A Multi-Centre Randomized and Double-Blind Controlled Trial of Rituximab for Warm Autoimune Hemolytic Anemia in Adults

Author:

Michel Marc123,Terriou Louis4,Roudot-Thoraval Françoise5,Hamidou Mohamed6,Ebbo Mikael78,Le guenno Guillaume9,Audia Sylvain10,Royer Bruno11,Morin anne-Sophie12,Michot Jean Marie13,Jaccard Arnaud1415,Frenzel Laurent16,Haioun Corinne17,Khellaf Mehdi18,Godeau Bertrand1

Affiliation:

1. Internal Medicine, French referral center for adult's immune cytopenia, Henri Mondor Hospital, AP-HP, UPEC University, Créteil, France

2. Hôpital Henri-Mondor, APHP, Créteil, France

3. Université Paris Est, Créteil, France

4. Department of Internal Medicine, Hôpital HURIEZ CHRU Lille, Lille, France

5. Department of Biostatistics and Public Health, Henri Mondo University Hospital, Université Paris-Est Créteil, Créteil, France

6. Department of Internal Medicine, Hôtel Dieu University Hospital, Nantes, France

7. Aix Marseille University, Marseille, France

8. Department of Internal Medicine, Timone University Hospital, Assistance Publique Hôpitaux de Marseille, Marseille, France

9. Service de médecine Interne, CHU Clermont-Ferrand, Clermont-Ferrand, France

10. Department of Internal Medicine and Clinical Immunology, University Hospital, Dijon, France

11. Hematology, Centre Hospitalier Universitaire, Amiens, France

12. department of Internal Medicine, Hopital Jean Verdier, Bondy, France

13. Department of Internal Medicine, Hopital Bicetre, Le Kremlin Bicetre, France

14. Department of Hematology, Centre National de Référence Maladies Rares: Amylose AL et Autres Maladies à Dépôts, CHU Limoges, Limoges, France

15. HoPital Dupuytren, Limoges Cedex 1, France

16. Department of Clinical Hematology, Hopital Necker, AP-HP, Paris, France

17. Lymphoid Malignancies Unit, AP-HP, Groupe Hospitalier Mondor, Créteil, France

18. Henri Mondor Hospital, AP-HP, UPEC University, Creteil, France

Abstract

Abstract Introduction: Warm autoimmune hemolytic anemia (wAIHA) is a rare autoimmune disease that can be life threatening especially in elderly patients. Rituximab has shown very promising efficacy in several uncontrolled studies and in one controlled trial for treating adult' wAIHA and it is commonly used off-label as a second-line treatment and as a corticosteroid-sparing agent. Methods: This phase 3 multicentre randomized (1/1 ratio) and double-blind controlled trial aimed to assess the efficacy and safety of rituximab compared to placebo for the treatment of adults with newly diagnosed wAIHA treated with prednisone. Inclusion criteria were: age ≥ 18 years with a confirmed diagnosis of wAIHA (hemoglobin level ≤ 10g/dL with hemolysis and a positive direct antiglobulin test with an anti-IgG ± anti-C3d pattern in the absence of any other cause of hereditary or acquired hemolytic anemia). Only patients previously treated with corticosteroids for less than 6 weeks could be included. Patients with secondary wAIHA (except for stage A chronic lymphocytic leukemia) were excluded. At time of inclusion, all patients were given prednisone at a daily dose of 1 mg/kg for 2 weeks and then tapered every 10 days according to a standardized procedure and stopped within 3 months in case of response. Eligible patients received in combination with prednisone (double-blind) 2 infusions of either rituximab (arm A) or placebo (arm B) at a fixed dose of 1,000 mg 2 weeks apart (on days 1 and 15 after randomization). The primary endpoint was the overall response rate (CR + PR) at 1 year in both arms. Complete remission (CR) was defined by a hemoglobin (Hb) level ≥11 g/dL (women) or 12 g/dL (men) without hemolysis (including a normal haptoglobin level) in the absence of any ongoing treatment for wAIHA, on 2 different occasions 4 weeks apart in the absence of recent transfusion. Partial remission (PR) was defined by a Hb level ≥ 10g/dL with at least a 2g increase from baseline in the absence of any other treatment than prednisone given at a daily dose ≤ 10 mg or recent transfusion. A non-response (NR) was defined by the need of receiving prednisone at a daily dose > 10mg to maintain a PR and/or any other treatment potentially active in wAIHA (i.e., splenectomy, immunosuppressors). The hypothesis for the calculation of the sample size (n = 32 patients, 16 in each arm) was, based on previous data from the literature, an 80% overall response rate (CR + PR) at 1 year in the RTX arm versus 20% in the placebo arm with an a risk of 5% and a b risk of 10%. Results: A total of 32 patients, 17 females (53%), with a mean age at inclusion of 71 (SD: 16) years were enrolled and randomized. The patients main characteristics (mean age, sex ratio, Hb and LDH levels, number of packed red cells transfused at diagnosis) were comparable in both arms. Twenty-eight patients were followed for at least 1 year and were evaluable for response. Three patients aged of 90, 84 and 87 from the placebo arm prematurely died versus none in the rituximab arm (p=0.073) and 1 patient from the placebo arm was prematurely withdrawn at Week 28 for severe anemia. At 1 year, in intention to treat, the overall response rate (CR + PR) was 75% (11 CR and 1 PR) in the rituximab arm versus 31% (5 CR) in the placebo arm (p value=0.032). Among the non-responders in the placebo arm, 6 patients were given azathioprine and 2 patients underwent splenectomy. There was no difference in the mean gammaglobulin level at 1 year between the 2 arms (8.1 ±2.2 g/l versus 7.7 ±1.5 g/l, p value 0.499). A total of 7 severe infections occurred during the first year of follow-up, 5 in the placebo group and 2 in the RTX group (p=0.39) including 2 cases of pneumocystosis (1 in each treatment arm) and 1 bilateral pneumonia due to Streptococcus pneumonia in the placebo arm. One severe pulmonary embolism occurred on day 15 in a 84-year-old woman in the placebo arm. Conclusion: Compared to placebo, rituximab given in combination with prednisone is an effective and safe option for treating adult patients with newly-diagnosed wAIHA leading to an overall response of 75% at one year. Disclosures Michel: Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; AMGEN: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; GSK: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Research Funding. Off Label Use: rituximab use in AIHA. Godeau:Roche: Research Funding; Amgen: Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Disease-modifying treatments for primary autoimmune haemolytic anaemia;Cochrane Database of Systematic Reviews;2021-03-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3